Jpmorgan Chase & CO Indaptus Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.1 Trillion
  • Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Indaptus Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14 shares of INDP stock, worth $29. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Previous 9 55.56%
Holding current value
$29
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024
BUY
$1.63 - $2.8 $8 - $14
5 Added 55.56%
14 $0
Q4 2023

Feb 12, 2024
BUY
$1.75 - $2.75 $3 - $5
2 Added 28.57%
9 $0
Q3 2023

Nov 14, 2023
BUY
$1.75 - $3.95 $12 - $27
7 New
7 $0

Others Institutions Holding INDP

# of Institutions
18
Shares Held
588K
Call Options Held
0
Put Options Held
0
View Full List

About Indaptus Therapeutics, Inc.

INDP Quotes by TradingView
  • Ticker INDP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,258,600
  • Market Cap $17.5M
  • Description
  • Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B v...
More about INDP
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email